Cited by 347Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment ResearchNeurological disorders and treatments

New evidence on the management of Lewy body dementia

Open access
Taylor, John-Paul, McKeith, Ian G, Burn, David J, Boeve, Brad F, Weintraub, Daniel, Bamford, Claire, Allan, Louise M, Thomas, Alan J +1 more·2020·The Lancet Neurology

Abstract

Dementia with Lewy bodies and Parkinson's disease dementia, jointly known as Lewy body dementia, are common neurodegenerative conditions. Patients with Lewy body dementia present with a wide range of cognitive, neuropsychiatric, sleep, motor, and autonomic symptoms. Presentation varies between patients and can vary over time within an individual. Treatments can address one symptom but worsen another, which makes disease management difficult. Symptoms are often managed in isolation and by different specialists, which makes high-quality care difficult to accomplish. Clinical trials and meta-analyses now provide an evidence base for the treatment of cognitive, neuropsychiatric, and motor symptoms in patients with Lewy body dementia. Furthermore, consensus opinion from experts supports the application of treatments for related conditions, such as Parkinson's disease, for the management of common symptoms (eg, autonomic dysfunction) in patients with Lewy body dementia. However, evidence gaps remain and future clinical trials need to focus on the treatment of symptoms specific to patients with Lewy body dementia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(19)30153-x

Cites

120 of 120 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A narrative review and a Delphi consensus group supported donepezil and rivastigmine for neuropsychiatric symptoms of dementia with Lewy bodies, although a network meta-analysis found these drugs improved neuropsychiatric symptoms in Parkinson's disease dementia but not in dementia with Lewy bodies.

    “A narrative review 124 and a Delphi consensus group 125 supported the use of donepezil and rivastigmine for neuropsychiatric symptoms of dementia with Lewy bodies, although a network meta‐analysis found that these drugs improved neuropsychiatric symptoms in Parkinson's disease dementia, but not in dementia with Lewy bodies 123 .”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [99]Schaeffer E, Berg D. Dopaminergic therapies for non-motor symptoms in Parkinson’s disease. CNS Drugs 2017; 31: 551– 70. 28643183

Cited by

Sorted by citations

Authors
Taylor, J.-P., McKeith, I. G., Burn, D. J., Boeve, B. F., Weintraub, D., Bamford, C., Allan, L. M., Thomas, A. J., & O'Brien, J. T.
Affiliations
  • Newcastle University (GB)
  • Mental Illness Research, Education and Clinical Centers (US)
  • University of Exeter (GB)
  • University of Cambridge (GB)
Corresponding author
Taylor, John-Paul
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2020-02
Volume
19
Issue
2
Pages
157-169
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2951808807
Cited by
347
References
120
Citations by year
2026: 29 · 2025: 75 · 2024: 61 · 2023: 56 · 2022: 51 · 2021: 47 · 2020: 24 · 2019: 2 · 2018: 1
FWCI
4.14
Type
journal article
Language
en
Open access
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Open Research Exeter (University of Exeter) (acceptedVersion, cc-by-nc-nd)
  • Figshare (submittedVersion, cc-by-nc-nd)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by-nc-nd)
Funders
  • National Institute for Health and Care Research (DTC-RP-PG-0311-12001, NF-SI-0611-10048)
  • National Institute on Aging (U19AG062418)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Neurology › Neurological disorders and treatments
Keywords
dementia with Lewy bodies, Parkinson's disease dementia, dementia management, cognitive symptoms, neuropsychiatric symptoms, motor symptoms, autonomic dysfunction, sleep symptoms, symptom management, multidisciplinary care
MeSH terms
Dementia, Humans, Parkinson Disease, Lewy Bodies, Neurodegenerative Diseases, Lewy Body Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review